Literature DB >> 23891820

Association between the Pro12Ala polymorphism of PPAR-γ gene and the non-alcoholic fatty liver disease: a meta-analysis.

Jun Wang1, Xufeng Guo, Pengbo Wu, Jia Song, Chuncui Ye, Shijie Yu, Jixiang Zhang, Weiguo Dong.   

Abstract

Several studies have been conducted to examine the association between PPAR-γ2 Pro12Ala polymorphism and non-alcoholic fatty liver disease (NAFLD), but the results remain inconsistent. In this study, a meta-analysis was performed to assess the association of PPAR-γ Pro12Ala polymorphism with NAFLD risk. A total of 8 case-control studies, including 1697 cases and 2427 controls, were selected. Pooled odds ratio (OR) with 95% confidence interval (CI) was calculated using fixed- or random-effects model. Overall, no evidence has indicated that the Pro12Ala polymorphism was associated with the susceptibility to NAFLD. Besides, stratified analysis with ethnicity also indicated that no significant association between PPAR-γ Pro12Ala and the risk of NAFLD under all for genetic model in both Asian and Caucasian populations was observed. This meta-analysis indicated that the Pro12Ala polymorphism is not associated with NAFLD risk. Large and well-designed studies are warranted to validate our findings.
© 2013.

Entities:  

Keywords:  CI; HWE; Hardy–Weinberg equilibrium; MS; Meta-analysis; NAFLD; NASH; Non-alcoholic fatty liver disease; OR; PPAR-γ; Polymorphism; SNP; confidence interval; metabolic syndrome; non-alcoholic fatty liver disease; non-alcoholic steatohepatitis; odds ratio; peroxisome proliferator activated receptor-γ; single nucleotide polymorphism

Mesh:

Substances:

Year:  2013        PMID: 23891820     DOI: 10.1016/j.gene.2013.07.014

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  8 in total

Review 1.  Genetic background in nonalcoholic fatty liver disease: A comprehensive review.

Authors:  Fabio Salvatore Macaluso; Marcello Maida; Salvatore Petta
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

Review 2.  Nonalcoholic fatty liver disease: a comprehensive review of a growing epidemic.

Authors:  Kareem Hassan; Varun Bhalla; Mohammed Ezz El Regal; H Hesham A-Kader
Journal:  World J Gastroenterol       Date:  2014-09-14       Impact factor: 5.742

Review 3.  Role of adipokines and peroxisome proliferator-activated receptors in nonalcoholic fatty liver disease.

Authors:  Vettickattuparambil George Giby; Thekkuttuparambil Ananthanarayanan Ajith
Journal:  World J Hepatol       Date:  2014-08-27

4.  Mechanism of action of gypenosides on type 2 diabetes and non-alcoholic fatty liver disease in rats.

Authors:  Qin He; Jin-Ke Li; Fang Li; Ru-Gui Li; Guo-Qing Zhan; Gang Li; Wei-Xing Du; Hua-Bing Tan
Journal:  World J Gastroenterol       Date:  2015-02-21       Impact factor: 5.742

Review 5.  Nonalcoholic fatty liver disease: molecular pathways and therapeutic strategies.

Authors:  Yue Ye Huang; Aaron M Gusdon; Shen Qu
Journal:  Lipids Health Dis       Date:  2013-11-09       Impact factor: 3.876

Review 6.  Gene polymorphisms associated with non-alcoholic fatty liver disease and coronary artery disease: a concise review.

Authors:  Xiao-Lin Li; Jian-Qing Sui; Lin-Lin Lu; Nan-Nan Zhang; Xin Xu; Quan-Yong Dong; Yong-Ning Xin; Shi-Ying Xuan
Journal:  Lipids Health Dis       Date:  2016-03-10       Impact factor: 3.876

Review 7.  Peroxisome Proliferator-Activated Receptors Associated with Nonalcoholic Fatty Liver Disease.

Authors:  Nan Wang; Rui Kong; Hui Luo; Xiaorong Xu; Jie Lu
Journal:  PPAR Res       Date:  2017-12-05       Impact factor: 4.964

8.  Association between APOC3 polymorphisms and non-alcoholic fatty liver disease risk: a meta-analysis.

Authors:  Jun Wang; Chuncui Ye; Sujuan Fei
Journal:  Afr Health Sci       Date:  2020-12       Impact factor: 0.927

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.